Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas H. Openshaw"'
Autor:
Xing Yi Woo, Anuj Srivastava, Philip C. Mack, Joel H. Graber, Brian J. Sanderson, Michael W. Lloyd, Mandy Chen, Sergii Domanskyi, Regina Gandour-Edwards, Rebekah A. Tsai, James Keck, Mingshan Cheng, Margaret Bundy, Emily L. Jocoy, Jonathan W. Riess, William Holland, Stephen C. Grubb, James G. Peterson, Grace A. Stafford, Carolyn Paisie, Steven B. Neuhauser, R. Krishna Murthy Karuturi, Joshy George, Allen K. Simons, Margaret Chavaree, Clifford G. Tepper, Neal Goodwin, Susan D. Airhart, Primo N. Lara, Thomas H. Openshaw, Edison T. Liu, David R. Gandara, Carol J. Bult
Publikováno v:
Cancer Res
Cancer research, vol 82, iss 22
Cancer research, vol 82, iss 22
Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for testing the efficacy of novel drugs and drug combinations for cancer therapeutics. Here we describe a repository of 79 genomically and clinically annotated lung
Autor:
Anita Giobbie-Hurder, Harold J. Burstein, Otto Metzger Filho, Thomas H. Openshaw, Rachel A. Freedman, Steven E. Come, Jeanna Hamilton Walsh, Bryan P. Schneider, Nan Lin, Meredith Faggen, Michael Constantine, Erica L. Mayer
Publikováno v:
Breast Cancer Research and Treatment. 185:135-144
Adverse events (AE) during oncology clinical trials are typically reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), which provides information about the frequency and severity of AEs from the provide
Autor:
Mark R. Somerfield, Andrea Eisen, Diana T. Chingos, Kimberly H. Allison, Praveen Vikas, N. Lynn Henry, Thomas H. Openshaw, Nofisat Ismaila, Carey K. Anders, Patricia A. Spears, Bruno Lemos Ferrari, Vered Stearns, Vandana G. Abramson
Publikováno v:
Journal of Clinical Oncology. 37:1965-1977
PURPOSE To update the American Society of Clinical Oncology endorsement of the Cancer Care Ontario recommendations on the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer. METHOD
Autor:
Mark R. Somerfield, Carey K. Anders, Arti Hurria, Vandana G. Abramson, Kimberly H. Allison, Diana T. Chingos, Ian E. Krop, N. Lynn Henry, Thomas H. Openshaw
Publikováno v:
Journal of Clinical Oncology. 34:2303-2311
Purpose An American Society of Clinical Oncology (ASCO) panel considered the Cancer Care Ontario (CCO) recommendations on the role of patient and disease factors in selecting adjuvant therapy for women with early-stage breast cancer for endorsement.